GC
HRMY icon

Guggenheim Capital’s Harmony Biosciences HRMY Stock Holding History

Guggenheim Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597K Buy
16,398
+8,678
+112% +$274K ﹤0.01% 1219
2026
Q1 		$216K Sell
7,720
-16,390
-68% -$537K ﹤0.01% 1503
2025
Q4 		$902K Buy
+24,110
New +$793K 0.01% 996

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Guggenheim Capital's HRMY Position: Q2 2026 in Review

Guggenheim Capital increased its Harmony Biosciences (HRMY) stake by 112% in Q2 2026, buying an estimated $274K and bringing the position to 16,398 shares worth $597K. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

Guggenheim Capital first reported a position in HRMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $902K in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Guggenheim Capital held 16,398 shares of Harmony Biosciences worth $597K as of Q2 2026.
  • Guggenheim Capital bought 8,678 Harmony Biosciences shares in Q2 2026, an estimated $274K.
  • Harmony Biosciences made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1219 holding.
  • Guggenheim Capital first reported a position in Harmony Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Guggenheim Capital's Harmony Biosciences position peaked at $902K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.